Want to see MANE full AI Analyst Report?
MANE Stock Chart & Stats
$98.51
--
Market closed
$98.51
--
Day’s Range― - ―
52-Week Range$32.00 - $131.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)679.63K
Market Cap
$4.92B
Enterprise Value$4.32K
Total Cash (Recent Filing)$819.89M
Total Debt (Recent Filing)$428.00K
Price to Earnings (P/E)―
Beta-0.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,780,136
10 Day Avg. Volume972,175
30 Day Avg. Volume679,625
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.94
Price to Sales (P/S)0.00
P/FCF Ratio-18.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$169.20Price Target Upside71.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Clinical EfficacyStatistically significant efficacy combined with favorable safety and tolerability provides important evidence for VDPHL01’s development potential. If ongoing pivotal studies replicate these results, the program could support regulatory progress, future commercialization, and a more durable business model.
Improved Financing RunwayFresh capital can extend operating runway while Veradermics advances clinical programs and works toward commercialization. Although financing does not create revenue, it reduces immediate liquidity pressure and gives management more time to generate value from positive development-stage assets.
Low Debt BurdenMinimal debt limits interest obligations and avoids the refinancing burden associated with highly leveraged businesses. The larger asset base may also provide operating resources as clinical development continues, giving the company some flexibility despite its broader funding needs.
Bears Say
Pre-commercial BusinessWith no reported revenue, Veradermics has not yet demonstrated commercial demand or an operating model capable of self-funding. Its future financial performance depends heavily on successful development, regulatory progress, and eventual product adoption rather than established recurring sales.
Rapidly Widening LossesThe sharp expansion in losses indicates substantially higher operating spending without corresponding revenue generation. Continued losses can consume capital before commercialization and make future earnings dependent on successful clinical execution, disciplined spending, and additional funding.
Accelerating Cash Burn And Negative EquityAccelerating cash outflows show that the business is not self-funding and may require continued external financing to sustain operations. Negative equity further weakens financial flexibility, increasing dependence on capital markets and raising the consequences of delays in development or commercialization.
Veradermics, Incorporated News
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
Veradermics, Incorporated lowest stock price was $32.00 and its highest was $131.24 in the past 12 months.
What is Veradermics, Incorporated’s market cap?
Veradermics, Incorporated’s market cap is $4.92B.
When is Veradermics, Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veradermics, Incorporated’s earnings last quarter?
Currently, no data Available
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 41,780,136 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Currently, no hedge funds are holding shares in MANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veradermics, Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$169.20 (71.76% Upside)
$169.20 (71.76% Upside)
Blogger Sentiment
Bullish
MANE Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 766.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 88.2%
Last 30 Days ▲ 88.2%
Learn more about TipRanks Smart Score
Company Description
Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
MANE Stock 12 Month Forecast
Average Price Target
$169.20
▲(71.76% Upside)
Technical Analysis
Vericel
―
Veracyte
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Caris Life Sciences, Inc.
―
Ownership Overview
18.03% Insiders
1.03% Mutual Funds
42.56% Other Institutional Investors
31.77% Public Companies and
Individual Investors